By Madeline Palauskas, Consultant and Katie Moses, Partner
Implications of Medicaid for Cell and Gene Therapies
Cell and gene therapies (CGTs) offer potentially curative outcomes in hematologic malignancies, genetic blood disorders, inherited metabolic diseases, and more. With more than 40 FDA-approved CGT products on the market as of 2025 and many more in development, getting patients access to treatment has become an increasing focus for pharma and biotech companies, with its own set of challenges.
Medicaid is central to that challenge, as many CGT-targeted conditions, including sickle cell disease (SCD), childhood cancers, and rare genetic disorders, disproportionately affect populations reliant on Medicaid. Since Medicaid is more than 50 separate programs, each with its own coverage process and payment methods, access improvements have historically struggled to keep pace with therapeutic innovation. As a result, FDA approval does not reliably lead to timely treatment for Medicaid patients, emphasizing the need for CGT companies to understand Medicaid access dynamics state by state.
Approval Does Not Mean Immediate Coverage
Federal law requires state Medicaid programs to cover FDA-approved drugs, including biologics such as CGTs, once the product’s company has signed a Medicaid Drug Rebate Agreement, with two caveats. First, a therapy paid within an inpatient bundle, such as a Diagnosis-Related Group (DRG) payment, must be carved out of that bundle to be considered a covered outpatient drug1. Second, required coverage is often slow in practice. Many states have no set timeline for updating their claims systems for a new product,2 and some restrict coverage pending internal Pharmacy & Therapeutics committee review, which can take six months to a year in select states2. Historical CAR-T precedent shows that approximately 56% of Medicaid fee-for-service (FFS) medical lives lack coverage policies within 12 months of FDA approval. Without a policy, sites face confusion on eligibility requirements and Medicaid processing slows.
Limited provider site availability creates a further barrier. CGTs are administered at a small number of qualified centers that are often geographically concentrated, so Medicaid patients may have no in-network option in their home state or city and must be treated elsewhere. When care is out of state, the treating provider must enroll with the patient’s home-state Medicaid program before coverage can be processed, adding weeks of delay.
Coverage Does Not Equate to Reimbursement
Similar to coverage, CGT reimbursement methodologies vary by state. Most state Medicaid programs pay for inpatient administration through a DRG, which combines product cost and all related services into one fixed amount, and for outpatient administration through a fee schedule. For provider sites offering CGTs, these approaches differ in favorability. DRG payments often fall short of product cost, even for CAR-T-specific DRGs, and Medicaid programs do not offer New Technology Add-On Payments (NTAP) like Medicare does2. While outpatient reimbursement is often viewed as more sustainable, Medicaid outpatient fee schedules may omit new products, list codes with no payment, or set rates well below Wholesale Acquisition Cost (WAC), driving reimbursement gaps. For example, Arizona and Vermont Medicaid programs reimburse approximately 80% of WAC for certain CAR-T products in the outpatient setting.
Since CGT product launches, there has been a strong push for product carve-outs. A Medicaid product carve-out means the CGT product is reimbursed separately from the standard payment method (e.g., DRG, ambulatory payment) in the state, which typically provides a more favorable arrangement for provider sites offering CGTs. As of 2025, 12 of 50 states had carve-outs in place for CAR-T products.
A National Movement Toward Addressing CGT Access Challenges
Led by the CMS Innovation Center, the Cell and Gene Therapy (CGT) Access Model marks the first time the federal government has negotiated outcomes-based agreements with pharma and biotech companies on behalf of state Medicaid agencies3. Participating states receive rebates if therapy does not deliver the expected outcomes. The model launched in January 2025 focused on SCD, and CMS is exploring adding other conditions as more CGTs are approved1. To date, the model includes 32 states plus the District of Columbia and Puerto Rico, representing 84% of Medicaid beneficiaries with SCD1. This broad uptake signals positive momentum for CGTs. It shows that many state Medicaid programs are willing to adopt outcomes-based terms and standardized access requirements, creating a template that could extend to other conditions.
While pharma and biotech companies agreed to outcomes-based terms, participating states committed to access requirements that aim to address coverage barriers. States must adopt a standardized access policy, pay for the therapy outside of the inpatient bundle, and align their managed care plans with the model. States must also contract with at least one qualified treatment center, in state or out of state, and ensure at least one of its providers is enrolled in their Medicaid program in advance1. However, the model covers only one disease area and two products, leaving all other CGT products subject to state-by-state access barriers.
Implications for Industry
A wave of pipeline CGTs is expected to come to market over the next few years, and each will enter the same state-level system. The ongoing access challenges for Medicaid patients highlight the need for dedicated Medicaid channel launch planning, particularly for CGTs in pediatric indications. That means assessing coverage and payment state by state before approval, prioritizing advocacy in the highest-risk states, and planning early for out-of-state treatment and outcomes-based terms. New therapies are reaching the market faster than Medicaid payment systems are adapting, creating access hurdles that must be addressed.
Learn how The Dedham Group’s expertise can support your cell and gene therapy Medicaid access strategy. Contact us.
References
- Centers for Medicare & Medicaid Services (CMS). CGT Access Model Frequently Asked Questions. Updated September 22, 2026. https://www.cms.gov/priorities/innovation/cgt-access-model-frequently-asked-questions
- Alliance for Regenerative Medicine (ARM) / ADVI Health. Issue Brief: Medicaid Barriers to Accessing Cell & Gene Therapies. November 2023. https://alliancerm.org/wp-content/uploads/2025/09/20231106-ARM_Medicaid-Access-Barriers-Issue_WEB.pdf
- CMS Newsroom. CMS Expands Access to Lifesaving Gene Therapies Through Innovative State Agreements. July 15, 2025. https://www.cms.gov/newsroom/press-releases/cms-expands-access-lifesaving-gene-therapies-through-innovative-state-agreements